SNMMI meeting offers a special focus on radium-223 dichloride

05/21/2013 | MolecularImaging.net

A number of education sessions at this year's SNMMI Annual Meeting will focus on the newly approved radium-223 dichloride, a targeted radioisotope therapy for castrate-resistant prostate cancer, writes SNMMI Outreach Committee Co-chair Dr. Andrei Iagaru. "This is an exciting time for nuclear medicine as alpha radiation is not routinely used as a treatment. Preliminary results are encouraging and many [patient] and referring physician organizations have expressed interest in the new therapy," Iagaru writes.

View Full Article in:

MolecularImaging.net

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Corporate Life Sciences Lawyer (3-5 years exp)
Ropes & Gray LLP
Boston, MA; San Francisco, CA; Silicon Valley, CA, MA
Director of Accreditation
Meridian Health Plan
Detroit, MI
Health Services Researcher
AARP
Washington, DC
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Senior director risk adjustor and coding doc
Novant Health
Charlotte, NC